Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors

Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).

(2019) Jaume Capdevila et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

(2019) Emily K. Bergsland et al.   JOURNAL OF CLINICAL ONCOLOGY

Serotonin decreases the production of Th1/Th17 cytokines and elevates the frequency of regulatory CD4+ T-cell subsets in multiple sclerosis patients

(2018) Priscila M. Sacramento et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset of human dendritic cells

(2018) Attila Szabo et al.   Scientific Reports

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer

(2018) Karine Pozo et al.   Oncotarget

Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).

(2017) Jennifer A. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy

(2016) K. Okkenhaug et al.   Cancer Discovery

The intestinal immunoendocrine axis: novel cross-talk between enteroendocrine cells and the immune system during infection and inflammatory disease: Figure 1

(2015) John J Worthington   BIOCHEMICAL SOCIETY TRANSACTIONS

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

(2015) T Eisen et al.   BRITISH JOURNAL OF CANCER

Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).

(2015) Daniel H. Palmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.

(2015) Ann-Lii Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes

(2014) Julie Hallet et al.   CANCER

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches

(2013) K. Oberg et al.   CLINICAL CANCER RESEARCH

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

(2011) G Bousquet et al.   BRITISH JOURNAL OF CANCER

Suppression of T-cell responses by tumor metabolites

(2011) Katrin Singer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tricyclic Antidepressant Amitriptyline Activates Fibroblast Growth Factor Receptor Signaling in Glial Cells

(2011) Kazue Hisaoka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients

(2010) P. M. Ellis et al.   CLINICAL CANCER RESEARCH

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

(2010) I. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

(2009) K. Mross et al.   CLINICAL CANCER RESEARCH

Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

(2008) Sofia Vikman et al.   ACTA ONCOLOGICA

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

(2008) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY